Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma

International Journal of Cancer

Volumn 134, Issue 1, 2014, Pages 102-113

  Del Campo, Ana B ^a,b   Kyte, Jon Amund ^c   Carretero, Javier ^a,b   Zinchencko, Svitlana ^a   Méndez, Rosa ^a   González Aseguinolaza, Gloria ^d   Ruiz Cabello, Francisco ^a,b   Aamdal, Steinar ^c   Gaudernack, Gustav ^c   Garrido, Federico ^a,b   Aptsiauri, Natalia ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF NAVARRA   (Spain)

Author keywords

beta2 microglobulin mutation; immune escape; metastatic melanoma; tumor HLA class I loss

Indexed keywords

BETA 2 MICROGLOBULIN; DENDRITIC CELL VACCINE; HLA ANTIGEN CLASS 1;

AGED; AMINO ACID SUBSTITUTION; ARTICLE; BETA2M GENE; CANCER CELL; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CHROMOSOME 15; CHROMOSOME 6; CHROMOSOME LOSS; EXON; GENE LOSS; GENE MUTATION; GENETIC CORRELATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE BIOPSY; LYMPHOCYTIC INFILTRATION; METASTATIC MELANOMA; MICROSATELLITE MARKER; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SHORT TANDEM REPEAT; STOP CODON; TUMOR ESCAPE; TUMOR GENE;

BETA2-MICROGLOBULIN MUTATION; IMMUNE ESCAPE; METASTATIC MELANOMA; TUMOR HLA CLASS I LOSS;

AGED; BETA 2-MICROGLOBULIN; CELL LINE, TUMOR; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; MELANOMA; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR ESCAPE;

EID: 84885957415     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28338     Document Type: Article

References (32)

1. Garrido F, Ruiz-Cabello F, Cabrera T, et al. Implications for immunosurveillance of altered. HLA class I phenotypes in human tumours. Immunol Today 1997; 18: 89-95.
2. Aptsiauri N, Cabrera T, Garcia-Lora A, et al. MHC class I antigens and immune surveillance in transformed cells. Int Rev Cytol 2007; 256: 139-89.
3. Drake CG, Jaffee E, Pardoll DM,. Mechanism of immune evasion by tumors. Adv Immunol 2006; 90: 51-81.
4. Marincola FM, Jafee EM, Hicklin DJ, et al. Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74: 181-273.
5. Rosenberg SA, Sherry RM, Morton KE, et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 2005; 175: 6169-76.
6. Boon T, Coulie PG, Van den Eynde BJ, et al. Human T cell responses against melanoma. Annu Rev Immunol 2006; 24: 175-208.
7. Seliger B, Maeurer MJ, Ferrone S,. Antigen processing machinery breakdown and tumor growth. Immunol Today 2000; 21: 455-64.
8. Garrido F, Cabrera T, Aptsiauri N., "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer 2010; 127: 249-56.
9. Carretero R, Wang E, Rodriguez AI, et al. Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int J Cancer 2012; 131: 387-95.
10. Aptsiauri N, Carretero R, Garcia-Lora A, et al. Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations. Cancer Immunol Immunother 2008; 57: 1727-33.
11. Wang E, Monaco A, Monsurró V, et al. Antitumor vaccines, immunotherapy and the immunological constant of rejection. Invest Drugs J 2009; 12: 297-301.
12. Benitez R, Godelaine D, Lopez-Nevot MA, et al. Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens 1998; 52: 520-9.
13. Paschen A, Arens N, Sucker A, et al. The coincidence of chromosome 15 aberrations and beta2-microglobulin gene mutations is causative for the total loss of human leukocyte antigen class I expression in melanoma. Clin Cancer Res 2006; 12 (11 Part 1): 3297-305.
14. Bernal M, Ruiz-Cabello F, Concha A, et al. Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes. Cancer Immunol Immunother 2012; 61: 1359-71.
15. Maleno I, Aptsiauri N, Cabrera T, et al. Frequent loss of heterozygosity in the b2-microglobulin region of chromosome 15 in primary human tumors. Immunogenetics 2011; 63: 65-71.
16. Rolland P, Deen S, Scott I, et al. Human leukocyte antigen class I antigen expression is an independent prognostic factor in ovarian cancer. Clin Cancer Res 2007; 13: 3591-6.
17. Méndez R, Ruiz-Cabello F, Rodríguez T, et al. Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy. Cancer Immunol Immunother 2007; 56: 88-94.
18. Restifo NP, Marincola FM, Kawakami Y, et al. Loss of functional beta(2)-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 1996; 88: 100-8.
19. Paschen A, Mendez RM, Jimenez P, et al. Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events. Int J Cancer 2003; 103: 759-67.
20. Baba T, Hanagiri T, Takenoyama M, et al. Identification of a lung cancer antigen evading CTL attack due to loss of human leukocyte antigen (HLA) class I expression. Cancer Sci 2010; 101: 2115-20.
21. Chang CC, Ogino T, Mullins DW, et al. Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells. J Biol Chem 2006; 281: 18763-73.
22. Yamshchikov GV, Mullins DW, Chang CC, et al. Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. J Immunol 2005; 174: 6863-71.
23. Pérez B, Benitez R, Fernández MA, et al. A new beta 2 microglobulin mutation found in a melanoma tumor cell line. Tissue Antigens 1999; 53: 569-72.
24. Kyte JA, Mu L, Aamdal S, et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther 2006; 13: 905-18.
25. Tsukahara T, Kawaguchi S, Torigoe T, et al. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Sci 2006; 97: 1374-80.
26. del Campo AB, Aptsiauri N, Méndez R, et al. Efficient recovery of HLA class I expression in human tumor cells after beta2-microglobulin gene transfer using adenoviral vector: implications for cancer immunotherapy. Scand J Immunol 2009; 70: 125-35.
27. García-Ruano AB, Méndez R, Romero JM, et al. Analysis of HLA-ABC locus-specific transcription in normal tissues. Immunogenetics 2010; 62: 711-19.
28. Maleno I, Romero JM, Cabrera T, et al. LOH at 6p21.3 region and HLA class I altered phenotypes in bladder carcinomas. Immunogenetics 2006; 58: 503-10.
29. Chang CC, Campoli M, Restifo NP, et al. Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy. J Immunol 2005; 174: 1462-71.
30. Serrano A, Tanzarella S, Lionello I, et al. Reexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2'-deoxycytidine treatment. Int J Cancer 2001; 94: 243-51.
31. del Campo AB, Carretero J, Aptsiauri N, et al. Targeting tumor HLA class I expression to increase tumor immunogenicity. Tissue Antigens 2012; 79: 147-54.
32. Somasundaram R, Villanueva J, Herlyn M,. Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations. Adv Pharmacol 2012; 65: 335-59.